Imexpharm (IMP) Leaders Sell Shares After Livzon Group Acquires 67.87% Stake
This Aveluro analysis covers IMP (Dược phẩm Imexpharm) in the Dược phẩm sector. The classified event type is stake change, with mixed sentiment and a deterministic market-impact score of 7.0/10. Source coverage came from CafeF - Thị trường chứng khoán, classified as a primary/top-tier source.
Follow this event and trade Vietnam stocks
Use the broker guide to compare Vietnam market access before acting on this news.
Aveluro may earn a commission from broker partners. Market data and broker availability can change; confirm access before opening an account.
Overview
Multiple leaders of Imexpharm (IMP) sold shares on May 7, 2026, shortly after Chinese pharmaceutical giant Livzon Group completed the acquisition of a 67.87% stake in the company via its subsidiary Lian SGP Holding Pte. Ltd. for nearly VND 6,000 billion (~$240 million). The transaction transfers control from SK Group to Livzon, a top-25 Chinese pharmaceutical firm, marking a significant ownership change for the HoSE-listed drugmaker.
Key Facts
- CEO Tran Thi Dao sold 371,400 IMP shares on May 7, reducing her stake from 0.44% to 0.2%.
- Deputy CEO Ngo Minh Tuan sold 156,000 IMP shares, lowering his holding to 0.1%.
- Deputy CEO Huynh Van Nhung sold 80,000 IMP shares, reducing his stake to 0.065%.
- Chief Accountant Duong Hoang Vu sold 12,000 IMP shares, leaving a 0.006% stake.
- Lian SGP Holding (Livzon’s subsidiary) acquired 104.5 million IMP shares at VND 57,400/share, totaling nearly VND 6,000 billion (~$240 million).
- The acquisition raised Lian SGP’s ownership from 0% to 67.87%, making it the parent company.
- SK Group sold its entire stake, with SK Investment Vina III reducing from 47.69% to 3%.
What Happened
According to regulatory filings, several top executives of Imexpharm (IMP) conducted share sales via negotiated transactions on May 7, 2026. CEO Tran Thi Dao, Deputy CEOs Ngo Minh Tuan and Huynh Van Nhung, and Chief Accountant Duong Hoang Vu all reduced their holdings. The sales come immediately after Lian SGP Holding Pte. Ltd., a wholly owned subsidiary of Livzon Pharmaceutical Group (China), completed the purchase of a 67.87% stake in Imexpharm from SK Group and other shareholders.
The acquisition, executed between April 17-21, 2026, involved the transfer of shares from SK Investment Vina III, Binh Minh Kim Investment JSC, and KBA Investment JSC. Livzon Group, established in 1985 with a charter capital of over CNY 935 million, is among the top 25 pharmaceutical companies in China and operates in over 30 countries.
Market Context
IMP shares closed at VND 46,850 on May 12, 2026, with low volume of 24,100 shares. The stock has been under pressure following the change in control announcement, as investors digest the implications of a Chinese parent company. The pharmaceutical sector on HoSE has seen mixed performance amid regulatory changes and foreign ownership dynamics.
Strategic Significance
The acquisition by Livzon Group provides Imexpharm with access to a global pharmaceutical network, potentially enhancing its R&D capabilities and product pipeline. However, the leadership share sales may signal uncertainty or a desire to lock in gains following the premium-priced tender offer (VND 57,400 vs. recent market price). The shift from SK Group, a Korean conglomerate, to a Chinese strategic owner could also affect IMP’s competitive positioning in the Vietnamese market, particularly in terms of regulatory approvals and market access.
What to Watch
- Further insider transactions or management changes as Livzon integrates IMP.
- Q2 2026 earnings report to assess operational impact under new ownership.
- Any strategic announcements regarding product launches or partnerships with Livzon.
- Foreign ownership levels and potential delisting or restructuring plans.
- Regulatory review by Vietnamese authorities of the cross-border acquisition.